NCT05605496View on ClinicalTrials.gov

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

February 24, 2026

Study Completion Date

November 24, 2026

Conditions
Advanced Solid TumorsMetastatic Solid Tumors
Interventions
DRUG

NP137

IV infusion, 14mg/kg, Q3W

DRUG

anti-PD-1/PD-L1

IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.

Trial Locations (5)

31059

NOT_YET_RECRUITING

Institut Claudius Regaud (IUCT Oncopole), Toulouse

67033

NOT_YET_RECRUITING

Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg

69008

RECRUITING

Centre Léon Bérard, Lyon

75005

NOT_YET_RECRUITING

Institut Curie, Paris

06189

NOT_YET_RECRUITING

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

NETRIS Pharma
All Listed Sponsors
collaborator

NETRIS Pharma

INDUSTRY

lead

Centre Leon Berard

OTHER

NCT05605496 - NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies | Biotech Hunter | Biotech Hunter